No Equivalence for Paclitaxel vs Doxorubicin/Cyclophosphamide

['lizbeth]

I stumbled on this looking for the results of the 4 vs 6 question, and posted it as a reminder to myself to go back and read the study details.

Interesting conclusions. I think the title is a bit dramatic for the information. A 1% overall survival benefit, and 9 treatment deaths in the doxorubicin/cyclophosphamide arm.

I think adjuvant TCH was a good treatment choice for the time, and ACTH for its time. With pCR, I see the industry shifting toward TCHP which has the highest pCR, and a move to subtyping research.

What was not obvious was the data on the 4 vs 6 treatments. It was mentioned that the enrollment in the 6 treatment arm slowed in accrual and was dropped in 2008.

Are the numbers above based on 4 treatments? If so it looks quite similar to the 6 treatment numbers of DFS and OS.